2025
Patients with fibromyalgia have increased risk of 90-day postoperative adverse events following arthroscopic rotator cuff repair
Rancu A, Katsnelson B, Sanchez J, Winter A, Vasudevan R, Grauer J. Patients with fibromyalgia have increased risk of 90-day postoperative adverse events following arthroscopic rotator cuff repair. JSES International 2025, 9: 360-365. DOI: 10.1016/j.jseint.2024.09.018.Peer-Reviewed Original ResearchRotator cuff repairPostoperative adverse eventsAdverse eventsArthroscopic rotator cuff repairCurrent Procedural TerminologyElixhauser Comorbidity IndexOccurrence of wound dehiscenceEmergency departmentUrinary tract infectionSymptomatic rotator cuff tearsAssociated with increased riskCuff repairLog-rank testYear of surgerySurgical site infectionSevere adverse eventsKaplan-Meier curvesAcute kidney injuryOccurrence of sepsisDeep vein thrombosisMinor adverse eventsRotator cuff repair patientsIndividual adverse eventsOdds of ED utilizationDiagnosis of fibromyalgiaComparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatientsAssociation between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.
Mohanna R, Simsek B, El Ahmar N, Jegede O, Matar S, Paul M, Nabil Laimon Y, Roberti De Oliveira G, Delcea A, Choueiri T, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial. Journal Of Clinical Oncology 2025, 43: 590-590. DOI: 10.1200/jco.2025.43.5_suppl.590.Peer-Reviewed Original ResearchAdvanced clear cell renal cell carcinomaClear cell renal cell carcinomaProgression-free survivalPD-1 expressionTumor-infiltrating TregsCell renal cell carcinomaRegulatory T cellsPD-1Renal cell carcinomaClinical trialsCell carcinomaT cellsEfficacy of PD-1 blockadeInhibition of PD-1 signalingLevel of PD-1 expressionShorter median progression-free survivalTumor-infiltrating regulatory T cellsAssociated with progression-free survivalMedian progression-free survivalPercentage of PD-1First-line nivolumabFirst-line settingPD-1 blockadePD-1 signalingLog-rank testCefazolin Alone Versus Cefazolin With Tobramycin or Gentamicin as Intraoperative Antibiotic Prophylaxis for Total Joint Arthroplasty
Dhodapkar M, Halperin S, Radford Z, Rubin L, Grauer J, Li M. Cefazolin Alone Versus Cefazolin With Tobramycin or Gentamicin as Intraoperative Antibiotic Prophylaxis for Total Joint Arthroplasty. Arthroplasty Today 2025, 31: 101613. PMID: 39911247, PMCID: PMC11794179, DOI: 10.1016/j.artd.2024.101613.Peer-Reviewed Original ResearchFive-year implant survivalTotal knee arthroplastyElixhauser Comorbidity IndexProphylactic cefazolinImplant survivalAdverse outcomesComorbidity indexTotal hip arthroplastyAntibiotic prophylaxis regimensIntraoperative antibiotic prophylaxisStandard prophylactic antibioticsKaplan-Meier analysisLog-rank testPerioperative adverse outcomesPostoperative adverse outcomesProsthetic joint infectionMultivariate logistic regressionAntibiotic prophylaxisProphylaxis regimensTotal knee arthroplasty patientsProphylactic antibioticsSSI ratesComplication of total knee arthroplastyJoint infectionCefazolinPostoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra P, Thorstad W, Nguyen-Tân P, Siu L, Holsinger F, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen S, Gwede C, Dicker A, Yao M, Jordan R, Dorth J, Lee N, Chan J, Dunlap N, Bar-Ad V, Stokes W, Chakravarti A, Sher D, Rao S, Harris J, Yom S, Le Q, Bar-Ad V, Bednarz G, Bowles D, Breen S, Burtness B, Chakravarti A, Chan J, Chung C, Cmelak A, Dicker A, Dorth J, Dunlap N, El-Naggar A, Gwede C, Harris J, Holsinger F, Jones C, Jordan R, Krempl G, Le Q, Lee N, Lominska C, Ma D, Machtay M, Mell L, Nguyen-Tan P, Quon H, Raben A, Rao S, Samuels S, Sher D, Siu L, Spencer S, Stokes W, Takiar V, Thorstad W, Torres-Saavedra P, Wilke C, Yao M, Yom S, Young M. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal Of Clinical Oncology 2025, jco2401829. PMID: 39841939, DOI: 10.1200/jco-24-01829.Peer-Reviewed Original ResearchDisease-free survivalOverall survivalToxicity ratesEpidermal growth factor receptor expressionGrowth factor receptor expressionHead and neck cancerHPV-negative diseaseIntermediate-risk cancerIntensity-modulated RTStratified log-rank testAcute toxicity ratesSecondary end pointsOral cavity cancerSquamous cell carcinomaLog-rank testHead and neckLong-term toxicityBenefit of RTFisher's exact testPostoperative RTCell carcinomaReceptor expressionNeck cancerOral cavityRadiotherapy
2024
Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria.
Aderibigbe A, Dare A, Kalvin H, Olasehinde O, Wuraola F, Adisa A, Omisore A, Komolafe A, Omoyiola O, Okereke C, Katung A, Egberoungbe A, Ariyibi O, Olatoke S, Adeyeye A, Agodirin S, Bojuwoye M, Fayenuwo J, Ademakinwa O, Osinowo D, Lawal A, Abdulkareem F, Goldman D, Knapp G, Murthy S, Kahn R, Gonen M, Kingham T, Alatise O. Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria. Journal Of Surgical Oncology 2024 PMID: 39574208, DOI: 10.1002/jso.27878.Peer-Reviewed Original ResearchEmergency presentationsOverall survivalColorectal cancerCRC patientsCancer control effortsAssociated with worse OSCancer family historyElective patientsEmergency patientsRisk factorsLower household incomeLow educational levelOutcome of colorectal cancerProspective multicenter cohort studyStage IV diseaseSurgery improves survivalConsecutive CRC patientsKaplan-Meier methodLog-rank testMulticenter cohort studyAnalysis of risk factorsAccessing careProximal cancersMedian OSIV diseaseInflammatory bowel disease is associated with greater odds of complications following posterior lumbar fusion and further amplified for patients exposed to monoclonal antibody biologics
Seddio A, Katsnelson B, Smith-Voudouris J, Gouzoulis M, Day W, Jabbouri S, Vasudevan R, Rubio D, Grauer J. Inflammatory bowel disease is associated with greater odds of complications following posterior lumbar fusion and further amplified for patients exposed to monoclonal antibody biologics. North American Spine Society Journal (NASSJ) 2024, 20: 100574. PMID: 39759221, PMCID: PMC11697407, DOI: 10.1016/j.xnsj.2024.100574.Peer-Reviewed Original ResearchPosterior lumbar fusionInflammatory bowel diseaseOdds ratioNational Inpatient SampleElixhauser Comorbidity IndexLumbar fusionBowel diseaseKaplan-Meier survival analysisEmergency departmentInflammatory bowel disease patientsLog-rank testMinor adverse eventsNon-IBD patientsIn-hospital dataMultivariate logistic regressionAssociated with greater oddsElevated odds ratiosReoperation rateSurgical complicationsSpine surgeryInferior outcomesPearlDiver databasePost-discharge outcomesAdult patientsAdverse eventsRADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING
Zhu J, Hager T, Chadha S, Sritharan D, Weiss D, Hossain S, Osenberg K, Moore N, Aneja S. RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING. Neuro-Oncology 2024, 26: viii74-viii74. PMCID: PMC11553274, DOI: 10.1093/neuonc/noae165.0296.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaWhole-brain radiotherapyTreated with chemotherapyOverall survivalHigh-risk groupPatient phenotypesCentral nervous system lymphomaPCNSL treatmentRisk of neurocognitive side effectsImaging biomarkersC-statisticOne-year OSTwo-year OSNervous system lymphomaAssociated with improved outcomesLog-rank testNeurocognitive side effectsTime-dependent AUCBrain radiotherapySystem lymphomaTumor volumeTumor sizeRisk stratificationAnalyses assessed differencesSub-analysisAddition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Podoltsev N, Sun Z, Litzow M, Paietta E, Roberts K, Zhang Y, Racevskis J, Lazarus H, Rowe J, Arber D, Wieduwilt M, Liedtke M, Bergeron J, Wood B, Zhao Y, Wu G, Chang T, Zhang W, Pratz K, Dinner S, Frey N, Gore S, Bhatnagar B, Atallah E, Uy G, Jeyakumar D, Lin T, Willman C, DeAngelo D, Patel S, Elliott M, Advani A, Tzachanis D, Vachhani P, Roy R, Sharon E, Little R, Erba H, Stone R, Mullighan C, Tallman M, Luger S, Mattison R. Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial. Blood 2024, 144: 4211-4211. DOI: 10.1182/blood-2024-207143.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationRelapse free survivalAcute lymphoblastic leukemiaWhite blood cell countOlder ptsOverall survivalBone marrowAllogeneic hematopoietic stem cell transplantationB-lineage acute lymphoblastic leukemiaRandomized phase III trialFlow cytometryMulti-color flow cytometryStratified multivariable Cox modelsIncreased treatment toxicityPeripheral blood blastsStratified log-rank testImprovement of OSHigh dose methotrexateImproved overall survivalMedian follow-upStem cell transplantationKaplan-Meier methodPhase III trialsEstimates of OSLog-rank testClinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Getz T, Kewan T, Bewersdorf J, Stempel J, Lanino L, Wei W, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Ball S, Chandhok N, Logothetis C, Bidikian A, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta M, Komrokji R, Zeidan A. Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database. Blood 2024, 144: 3219-3219. DOI: 10.1182/blood-2024-202075.Peer-Reviewed Original ResearchNon-complex karyotypeInternational Prognostic Scoring SystemCytogenetic risk groupHMA initiationComplex karyotypeIPSS-RHypomethylating agentsOverall survivalRisk groupsCytogenetic abnormalitiesAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationAssociated with worse survivalHypomethylating agent combinationsPoor-risk cytogeneticsPeripheral blood blastsTreated with azacitidinePrognostic Scoring SystemMeasured overall survivalStem cell transplantationKaplan-Meier methodLog-rank testOutcomes of PTTime-to-event analysisRisk of patientsComparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.Peer-Reviewed Original ResearchMorphologic leukemia-free stateComposite complete remissionTreated with ICIntensive chemotherapyMonosomal karyotypeComplex karyotypeProgressive diseaseSurvival outcomesTreatment strategiesAllogeneic hematopoietic stem cell transplantationComposite complete remission rateTreated with intensive chemotherapyHematopoietic stem cell transplantationComparative analysis of outcomesDismal survival outcomesConventional cytotoxic chemotherapyAggressive disease biologyMulticenter retrospective cohortStem cell transplantationAnalyze survival outcomesKaplan-Meier methodLog-rank testAnalysis of outcomesCK-AMLCPX-351Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.Peer-Reviewed Original ResearchAcute myeloid leukemiaMedian OSTP53 co-mutationsTreated with ICIntensive chemotherapyComposite CRCo-mutationsComplete remissionOverall survivalPts ageAllogeneic stem cell transplantationSecondary acute myeloid leukemiaDiagnosed AMLAcute myeloid leukemia patientsAssociated with poor outcomesEstimate overall survivalStem cell transplantationKaplan-Meier methodLog-rank testPredictors of survivalCPX-351Monosomy 5MRD negativityInduction therapyComplex karyotypeLower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair
Seddio A, Moran J, Gouzoulis M, Garbis N, Salazar D, Grauer J, Jimenez A. Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair. Arthroscopy The Journal Of Arthroscopic And Related Surgery 2024, 41: 199-206. PMID: 39490542, DOI: 10.1016/j.arthro.2024.09.057.Peer-Reviewed Original ResearchArthroscopic rotator cuff repairT2DM patientsRotator cuff retearRotator cuff repairElixhauser Comorbidity IndexAdverse eventsLow risk of postoperative complicationsOdds ratioRisk of postoperative complicationsKaplan-Meier survival analysisUrinary tract infectionSurgical-site infectionCuff repairLog-rank testRetrospective comparative studyAcute kidney injuryMinor adverse eventsType II diabetes mellitusAssociated with decreased oddsMultivariate logistic regressionArthroscopic shoulder proceduresII diabetes mellitusAdministrative billing codesPostoperative complicationsTract infectionsImpact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty
Smith-Voudouris J, Dhodapkar M, Halperin S, Cohen J, Grauer J. Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty. JAAOS Global Research And Reviews 2024, 8: e23.00267. PMID: 39436712, PMCID: PMC11498930, DOI: 10.5435/jaaosglobal-d-23-00267.Peer-Reviewed Original ResearchConceptsAtopic dermatitisAdverse eventsOdds of pneumoniaTotal knee arthroplastyPerioperative outcomes of patientsModerate-to-severe diseaseIncreased oddsEmergency departmentUrinary tract infectionChronic inflammatory skin conditionOutcomes of patientsLog-rank testRisk of adverse eventsInflammatory skin conditionIncreased odds of pneumoniaKnee arthroplastyTotal knee arthroplasty patientsPerioperative outcomesImmunosuppressive medicationsTract infectionsAggregate adverse eventsAdult patientsImpact of atopic dermatitisPatient characteristicsMultivariate analysisRisk of Postoperative Complications After Total Hip and Total Knee Arthroplasty in Behcet Syndrome Patients
Ratnasamy P, Diatta F, Allam O, Kauke-Navarro M, Grauer J. Risk of Postoperative Complications After Total Hip and Total Knee Arthroplasty in Behcet Syndrome Patients. JAAOS Global Research And Reviews 2024, 8: e24.00040. PMID: 39392934, PMCID: PMC11469891, DOI: 10.5435/jaaosglobal-d-24-00040.Peer-Reviewed Original ResearchConceptsBehcet's syndromeAdverse eventsTotal knee arthroplastyMultivariate analysisRevision surgeryRisk of postoperative complicationsRisk of perioperative adverse eventsTotal hip arthroplastyLog-rank testElixhauser Comorbidity Index scoreRetrospective cohort studyMultisystem autoimmune disorderPostoperative adverse eventsPerioperative adverse eventsComorbidity Index scoreNational administrative databaseKnee arthroplastyTotal knee arthroplasty patientsPostoperative complicationsNo significant differencePatient ageAutoimmune disordersPerioperative managementSyndrome patientsCohort studyComplete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Ninia J, Verma N, Laird J, Hayman T, Knowlton C, Peters G, Campbell A, Housri N, Feghali K, de Jong D, Park H. Complete vs. Incomplete Consolidative Radiotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e51. DOI: 10.1016/j.ijrobp.2024.07.1890.Peer-Reviewed Original ResearchExtensive-stage small cell lung cancerProgression-free survivalSmall cell lung cancerOverall survivalCell lung cancerOligometastatic diseaseChemo-immunotherapyLung cancerSuperior progression-free survivalMedian follow-up timePatients treated with CCSites of disease involvementConsolidative thoracic radiotherapyAssociated with improved outcomesChemotherapy-based treatmentStratified Cox proportional hazard regressionsLog-rank testCox proportional hazards regressionDisease burdenTime of diagnosisKaplan-Meier estimatesProportional hazards regressionConsolidation radiotherapyPolymetastatic diseaseOligometastatic patientsEvaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selectionTestosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
Moningi S, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Taplin M, Kollmeier M, Hoffman K. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e563-e564. DOI: 10.1016/j.ijrobp.2024.07.1247.Peer-Reviewed Original ResearchMonths of GnRH agonistTestosterone recoveryGnRH agonistAssociated with lackClinically meaningful changeBaseline testosteroneAssociated with testosterone recoveryMedian follow-upEvaluated prior to treatmentTreatment groupsTrial randomized patientsHormonal functionPatient-reported health-related quality of lifeLog-rank testCompletion of treatmentMultivariate logistic regressionWilcoxon rank-sumPatient-reported HRQoL.Salvage radiationGleason scoreAbiraterone acetateHigher PSARecovery 1 yearRandomized patientsHealth-related quality of lifeA Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer
Laseinde E, Guan L, Hildebrand R, Meurice N, Gensheimer M, Beadle B, Holsinger F, Sunwoo J, Baik F, Sirjani D, Divi V, Kaplan M, Pinto H, Colevas A, Rahman M, Le Q. A Survival Analysis of Patients with Radiation-Induced Cancers after Prior Radiation for Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e764. DOI: 10.1016/j.ijrobp.2024.07.1678.Peer-Reviewed Original ResearchHead and neck cancerNonsurgical groupNeck cancerRadiation treatmentTreated with non-surgical therapyIRB-approved retrospective reviewSurvival rateKaplan-Meier survival curvesSurvival rate of patientsNon-surgical therapySurvival analysis of patientsLog-rank testAnalysis of patientsNon-surgical groupNon-surgical treatmentRate of patientsRadiation-induced cancerCompare survival ratesPrior RTPostoperative RTMedian followPrior radiationSquamous histologyOverall survivalMedian ageP31. Testosterone replacement therapy associated with increased 90-day postoperative adverse events and 5-year reoperation following lumbar discectomy
Seddio A, Gouzoulis M, Smith-Voudouris J, Rubio D, Day W, Grauer J. P31. Testosterone replacement therapy associated with increased 90-day postoperative adverse events and 5-year reoperation following lumbar discectomy. The Spine Journal 2024, 24: s78. DOI: 10.1016/j.spinee.2024.06.052.Peer-Reviewed Original ResearchTestosterone replacement therapyAcute kidney injuryLumbar discectomyAdverse eventsMale patientsOdds ratioCurrent Procedural TerminologyReoperation ratePostoperative outcomesElixhauser Comorbidity IndexPostoperative recoveryMultivariate analysisSingle-level lumbar discectomyTestosterone replacement therapy patientsMyocardial infarctionOrthopedic surgeryKaplan-Meier survival analysisEmergency departmentLumbar spinal proceduresLog-rank testMonths of surgeryRetrospective cohort studyPostoperative adverse eventsEnhanced postoperative recoveryMinor adverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply